keyword
MENU ▼
Read by QxMD icon Read
search

Pet psma

keyword
https://www.readbyqxmd.com/read/28408532/-68-ga-thp-psma-a-pet-imaging-agent-for-prostate-cancer-offering-rapid-room-temperature-one-step-kit-based-radiolabeling
#1
Jennifer D Young, Vincenzo Abbate, Cinzia Imberti, Levente K Meszaros, Michelle T Ma, Samantha Y A Terry, Robert C Hider, Greg E Mullen, Philip J Blower
The clinical impact and accessibility of (68)Ga tracers for the prostate-specific membrane antigen (PSMA) and other targets would be greatly enhanced by the availability of a simple, one-step kit-based labeling process. Radiopharmacy staff are accustomed to such procedures in the daily preparation of (99m)Tc radiopharmaceuticals. Currently, chelating agents used in (68)Ga radiopharmaceuticals do not meet this ideal. AIM: To develop and evaluate preclinically a (68)Ga radiotracer for imaging PSMA expression that could be radiolabeled simply by addition of (68)Ga generator eluate to a cold kit...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28408531/-68-ga-psma-11-pet-ct-interobserver-agreement-for-prostate-cancer-assessments-an-international-multicenter-prospective-study
#2
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, Christina Bluemel, Nina Eberhardt, Louise Emmett, Pawan Gupta, Markus Hartenbach, Thomas A Hope, Shozo Okamoto, Christian Helmut Pfob, Thorsten D Pöppel, Christoph Rischpler, Sarah Schwarzenböck, Vanessa Stebner, Marcus Unterrainer, Helle D Zacho, Tobias Maurer, Christian Gratzke, Alexander Crispin, Johannes Czernin, Ken Herrmann, Matthias Eiber
Background: The interobserver agreement for (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) study interpretations in patients with prostate cancer is unknown. Methods:(68)Ga-PSMA-11 PET/CT was performed in 50 patients with prostate cancer for biochemical recurrence (n = 25), primary diagnosis (n = 10), biochemical persistence after primary therapy (n = 5) or staging of known metastatic disease (n = 10). Images were reviewed by 16 observers who used a standardized approach for interpretation of local (T), nodal (N), bone (Mb), or visceral (Mc) involvement...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28408526/gallium-68-or-fluorine-18-for-prostate-cancer-imaging
#3
Claudia Kesch, Clemens Kratochwil, Walter Mier, Klaus Kopka, Frederik L Giesel
The introduction of prostate specific membrane antigen (PSMA)-positron emission tomography (PET) using (68)Ga revolutionized prostate cancer imaging. Outperforming standard imaging, it allows complete staging of the local tumor and possible lymph nodes, visceral or bone metastases with high accuracy in only one examination (1,2). Sensitivities of 66% and specificities of 99% were observed for primary lymph node staging. Moreover, it has become an excellent staging tool for recurrent prostate cancer even at early stage and low PSA levels...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28401244/integrated-68-ga-hbed-cc-psma-pet-mri-in-patients-with-suspected-recurrent-prostate-cancer
#4
Susanne Lütje, Joseph Cohnen, Benedikt Gomez, Johannes Grüneisen, Lino Sawicki, Herbert Rübben, Andreas Bockisch, Lale Umutlu, Thorsten D Pöppel, Axel Wetter
AIM: Evaluate the diagnostic accuracy of (68)Ga-labeled HBED-CC-PSMA-PET/MRI for detection of recurrent PCa in comparison to PET/CT. METHODS: 48 patients with suspected recurrent PCa underwent PET/CT after injection of the (68)Ga-HBED-CC-PSMA ligand followed by integrated PET/MRI. Image analysis was performed by nuclear medicine physicians and radiologists with respect to the detection of lymph node metastases, bone metastases and local recurrence of the tumour...
April 12, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28396816/psma-pet-ct-positive-paget-disease-in-a-patient-with-newly-diagnosed-prostate-cancer-imaging-and-bone-biopsy-findings
#5
Michael Froehner, Marieta Toma, Klaus Zöphel, Vladimir Novotny, Michael Laniado, Manfred P Wirth
A 67-year-old man diagnosed with Gleason score 4 + 5 = 9 clinically localized prostate cancer with (68)Ga-labeled prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography (PSMA-PET/CT) positive Paget bone disease is described. Immunohistochemical staining revealed weak PSMA positivity of the bone lesion supporting the hypothesis that neovasculature might explain positive PSMA-PET/CT findings in Paget disease.
2017: Case Reports in Urology
https://www.readbyqxmd.com/read/28368893/early-detection-of-bilateral-testicular-metastases-from-prostatic-adenocarcinoma-using-68ga-psma-ligand-pet-ct
#6
Desiree Weiberg, Herbert Radner, Thorsten Derlin, Walter F Thon
We present the case of a 76-year-old man with biochemical relapse after primary therapy for prostate cancer. Ga prostate-specific membrane antigen (PSMA) ligand PET/CT performed for localization of recurrent disease revealed bilateral metastases to the testes. Histopathologic evaluation after bilateral orchiectomy revealed testicular metastases. Metastases to the testes are rare and usually seen in advanced stages. Ga-PSMA ligand PET/CT is a highly sensitive and specific imaging method for the detection of primary and metastatic prostate cancer and has refined diagnostic approaches...
March 31, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28368889/image-of-the-month-multifocal-68ga-prostate-specific-membrane-antigen-ligand-uptake-in-the-skeleton-in-a-man-with-both-prostate-cancer-and-multiple-myeloma
#7
Isabel Rauscher, Tobias Maurer, Katja Steiger, Markus Schwaiger, Matthias Eiber
Ga prostate-specific membrane antigen (PSMA) HBED-CC PET/CT in a 65-year-old man with first diagnosis of prostate cancer (PC) and a history of multiple myeloma showing multifocal PSMA ligand uptake in the skeleton with corresponding osteolytic lesions in CT. Although osteolytic bone metastases are very rare in PC, PSMA expression in PET raised the suspicion of PC bone metastases. Bone marrow biopsy excluded PC metastases with immunohistochemistry showing endothelial expression of PSMA in small vessels within the myeloma...
March 31, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28368887/uptake-of-an-acrochordon-incidentally-detected-on-68ga-prostate-specific-membrane-antigen-pet-ct
#8
Gozde Daglioz Gorur, Turkay Hekimsoy, Serkan Isgoren, Aysun Sikar Akturk, Hakan Demir
Ga prostate-specific membrane antigen (PSMA) PET/CT is a promising tool for imaging of prostate cancer. Ga-PSMA PET/CT uptake of prostate cancer and its metastases are reflective of significant overexpression of PSMA. However, PSMA expression of benign neoplasms and nonprostate epithelial malignancies is not very well defined. We report a moderate Ga-PSMA uptake of an acrochordon (skin tag), which was incidentally found in a patient referred for staging prostate cancer. Acrochordon is a frequent, small, soft, skin-colored or hyperpigmented, benign, and usually pedunculated neoplasm of the skin...
March 31, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28368885/68ga-psma-pet-ct-uptake-in-intramuscular-myxoma-imitates-prostate-cancer-metastasis
#9
Helle D Zacho, Julie B Nielsen, Katja Dettmann, Sonja H Hjulskov, Lars J Petersen
Ga-PSMA PET/CT is becoming the most promising imaging modality for detecting recurrent prostate cancer. The modality has the advantage of being able to detect recurrent disease, even at very low prostate-specific antigen levels. However, several studies report Ga-PSMA uptake in tissue unrelated to prostate cancer. We present a 74-year-old man who underwent Ga-PSMA PET/CT for recurrent prostate cancer 5 years after radical prostatectomy. The Ga-PSMA PET/CT showed an intramuscular lesion with increased PSMA uptake in the left vastus medialis muscle...
March 31, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28349676/flourodeoxyglucose-positron-emission-tomography-scan-may-be-helpful-in-the-case-of-ductal-variant-prostate-cancer-when-prostate-specific-membrane-antigen-ligand-positron-emission-tomography-scan-is-negative
#10
Louise M McEwan, David Wong, John Yaxley
Gallium-68 prostate specific membrane antigen ligand (Ga-68 PSMA) positron emission tomography/computed tomography (PET/CT) scanning is emerging as a useful imaging modality for the staging of suspected and known recurrent or metastatic prostate cancer and in staging of newly diagnosed higher grade prostate cancer. However, we have observed at our institution that in some cases of the more aggressive ductal variant, Ga-68 PSMA uptake has sometimes been poor compared with prominent 18-flourodeoxyglucose (F-18 FDG) avidity seen in F-18 FDG PET/CT, which would suggest that FDG PET/CT scans are important in staging of ductal pattern prostate cancer...
March 28, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28346248/68ga-psma-pet-ct-in-osteosarcoma-in-fibrous-dysplasia
#11
Arun Sasikumar, Ajith Joy, M R A Pillai, Tony M Alex, Geetha Narayanan
Fibrous dysplasia (FD) is a benign bone lesion with a rare but potential for malignant transformation. Neither Tc-MDP nor F-FDG PET/CT can differentiate between FD and areas of malignant transformation in FD. We described a case of osteosarcoma developing in FD with selective uptake of tracer in malignant transformation areas demonstrated on a Ga-PSMA PET/CT scan. Our case highlights the ability of Ga-PSMA PET/CT to map tumor neoangiogenesis in osteosarcoma arising in FD, which can have potential implications in prognostication, possibility of antiangiogenesis-based therapeutic options, and in response assessment following chemotherapy...
March 24, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28338640/metal-based-psma-radioligands
#12
REVIEW
Eleni Gourni, Gjermund Henriksen
Prostate cancer is one of the most common malignancies for which great progress has been made in identifying appropriate molecular targets that would enable efficient in vivo targeting for imaging and therapy. The type II integral membrane protein, prostate specific membrane antigen (PSMA) is overexpressed on prostate cancer cells in proportion to the stage and grade of the tumor progression, especially in androgen-independent, advanced and metastatic disease, rendering it a promising diagnostic and/or therapeutic target...
March 24, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28336288/incidental-malignancies-identified-during-staging-for-prostate-cancer-with-68-ga-psma-hbed-cc-pet-imaging
#13
Andre Joshi, Cheryl Nicholson, Handoo Rhee, Sonja Gustafson, Ken Miles, Ian Vela
The rapid uptake of 68Ga Prostate-Specific Membrane Antigen (PSMA) HBED-CC PET imaging for prostate cancer staging has led to concerns regarding its specificity, with uptake in both malignant and non-malignant tissues. We describe three separate malignancies identified on 68Ga PSMA HBED-CC PET imaging. The misnomer of "prostate specific membrane antigen" is demonstrated by this case and highlights the importance of continued investigation of the potential role for 68Ga PSMA HBED-CC PET in other malignancies...
March 20, 2017: Urology
https://www.readbyqxmd.com/read/28319497/vertebral-hemangioma-mimicking-bone-metastasis-in-68ga-psma-ligand-pet-ct
#14
Carlos Artigas, François-Xavier Otte, Marc Lemort, Roland van Velthoven, Patrick Flamen
Ga-PSMA PET/CT was performed in a 68-year-old man to evaluate recurrent prostate cancer due to elevated serum prostate-specific antigen level. Images showed a focal uptake in the prostatic gland, suggesting local relapse, and an intense uptake in the 12th thoracic vertebra, with no morphological abnormalities in CT slices. In order to confirm extraprostatic disease and before radiotherapy planning, a full-spine MRI was performed, resulting with the morphological pattern of a vertebral hemangioma. Hystological analysis confirmed the local relapse in the prostate...
May 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28319496/the-utility-of-68ga-psma-pet-ct-in-poorly-differentiated-metastatic-prostate-cancer
#15
Mehmet Onur Demirkol, Murat Can Kiremit, Omer Acar, Burcu Ucar, Yesim Saglican
We aimed to emphasize how useful PSMA PET/CT findings can be while trying to restage prostate cancer after radical prostatectomy in the presence of low prostate-specific antigen values. A 64-year-old man with pT3b N1 M0 Gleason 7 adenocarcinoma of the prostate presented 5 years postoperatively with a palpable axillary mass, whereas his prostate-specific antigen was 0.08 ng/mL. Conventional imaging studies and histopathologic findings of the axillary mass biopsy revealed inconclusive results. Ga-PSMA PET/CT demonstrated PSMA-positive metastatic lesions, the largest one being located in the right axilla...
May 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28317152/-68-ga-psma-pet-for-radiation-treatment-planning-in-prostate-cancer-recurrences-after-surgery-individualized-medicine-or-new-standard-in-salvage-treatment
#16
Gregor Habl, Katharina Sauter, Kilian Schiller, Sabrina Dewes, Tobias Maurer, Matthias Eiber, Stephanie E Combs
BACKGROUND: (68) Ga-PSMA-PET imaging is a novel promising diagnostic tool to locate early biochemical failure after radical prostatectomy (RP) in prostate cancer (PC) patients. Exact knowledge of the relapse location may result in changes of the therapy concept aside from changes to the TNM stage. To gain data for this approach, we evaluated PC patients receiving (68) Ga-PSMA-PET imaging before salvage radiotherapy (RT). METHODS AND MATERIALS: In this study, 100 patients with biochemical failure after RP± prior RT who underwent (68) Ga-PSMA PET/CT or PET/MRI were evaluated undergoing salvage RT in our department...
June 2017: Prostate
https://www.readbyqxmd.com/read/28314971/-when-is-surgical-treatment-indicated-in-metastatic-prostate-cancer-and-what-is-the-scientific-rationale
#17
A Kretschmer, A Herlemann, C G Stief, C Gratzke
BACKGROUND: Recent improvements in imaging diagnostics has led to a rising incidence of oligometastatic prostate cancer and, most notably, an increasing incidence of nodal-only biochemical recurrences. In this clinical setting, systemic therapy is still the treatment of choice. However, there is increasing evidence for surgical approaches in this challenging clinical setting. AIM OF THE STUDY: In this comprehensive review article, current evidence regarding surgical approaches of primary nodal metastases, nodal-only biochemical recurrence following radical prostatectomy, and osseous metastatic prostate cancer will be discussed...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28314292/-68-ga-psma-ligand-pet-ct-based-radiotherapy-for-lymph-node-relapse-of-prostate-cancer-after-primary-therapy-delays-initiation-of-systemic-therapy
#18
Christoph Henkenberens, Christoph A VON Klot, Tobias L Ross, Frank M Bengel, Hans-Jürgen Wester, Hüper Katja, Hans Christiansen, Thorsten Derlin
AIM: To evaluate (68)Ga-PSMA ligand positron-emission tomography-computed tomography (PET/CT)-based radiotherapy for lymph node metastases of prostate cancer after primary therapy. PATIENTS AND METHODS: Twenty-three patients received radiotherapy for PSMA ligand-positive lymph node metastases. RESULTS: The median follow-up time was 12.4 (range=6.0-28.5) months. The median pre-treatment prostate-specific antigen (PSA) decreased from 2.75 (range=0...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28303694/lutetium-177-psma-radionuclide-therapy-for-men-with-prostate-cancer-a-review-of-the-current-literature-and-discussion-of-practical-aspects-of-therapy
#19
REVIEW
Louise Emmett, Kathy Willowson, John Violet, Jane Shin, Ashley Blanksby, Jonathan Lee
Prostate-specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high-binding affinity for the PSMA receptor have allowed high quality, highly specific PET imaging, in addition to the development of targeted radionuclide therapy for men with prostate cancer. This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelled PSMA peptides...
March 2017: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/28283702/-68-ga-psma-pet-ct-joint-eanm-and-snmmi-procedure-guideline-for-prostate-cancer-imaging-version-1-0
#20
Wolfgang P Fendler, Matthias Eiber, Mohsen Beheshti, Jamshed Bomanji, Francesco Ceci, Steven Cho, Frederik Giesel, Uwe Haberkorn, Thomas A Hope, Klaus Kopka, Bernd J Krause, Felix M Mottaghy, Heiko Schöder, John Sunderland, Simon Wan, Hans-Jürgen Wester, Stefano Fanti, Ken Herrmann
The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of (68)Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of (68)Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.
June 2017: European Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
110902
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"